BeiGene Receives New Approvals for BRUKINSA (zanubrutinib) in China

BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235),

Related Keywords

United States ,Beijing ,China ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Chinese ,Gabrielle Zhou ,Lai Wang ,Kevin Mannix ,Ma Jun ,Lymphoma Research Foundation ,China National Medical Products Administration ,National Cancer Institute ,Chinese Society Of Clinical Oncology ,End Results Program ,American Cancer Society ,Supervisor Of Supervisory Committee ,Harbin Institute Of Hematology Oncology ,Exchange Commission ,Supplemental New Drug Applications ,Supplemental Applications ,Gene Beigene Receives New Approvals ,Business Wire ,Global Head ,Healthy China ,Professor Ma Jun ,Harbin Institute ,Hematology Oncology ,Chief Supervisor ,Supervisory Committee ,Chinese Society ,Chronic Lymphocytic Leukemia ,Small Lymphocytic Lymphoma ,Private Securities Litigation Reform Act ,Chronic Lymphocytic ,Small Lymphocytic ,National Cancer ,End Results ,Cancer Stat Facts ,Accessed October ,Graw Hill Education ,American Cancer ,Updated May ,Lymphoma Research ,Accessed December ,Cancer Journal ,Beigene ,Eceives ,Approvals ,Brukinsa ,Zanubrutinib ,